research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:40:06 ON 22 JUL 2003

=> file .jacob
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:40:14 ON 22 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

200 2015227

FILE 'BIOSIS' ENTERED AT 13:40:14 ON 22 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 13:40:14 ON 22 JUL 2003

FILE 'EMBASE' ENTERED AT 13:40:14 ON 22 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:40:14 ON 22 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> francois l/au
L1 16 FILE CAPLUS
L2 9 FILE BIOSIS
L3 4 FILE MEDLINE
L4 5 FILE EMBASE
L5 0 FILE USPATFULL

TOTAL FOR ALL FILES
L6 34 FRANCOIS L/AU

=> marc b/au
L7 0 FILE CAPLUS
L8 18 FILE BIOSIS
L9 32 FILE MEDLINE
L10 45 FILE EMBASE
L11 0 FILE USPATFULL

TOTAL FOR ALL FILES
L12 95 MARC B/AU

=> l6 and l12
L13 0 FILE CAPLUS
L14 0 FILE BIOSIS
L15 0 FILE MEDLINE
L16 0 FILE EMBASE
L17 0 FILE USPATFULL

TOTAL FOR ALL FILES
L18 0 L6 AND L12

=> l6 and CD8
L19 0 FILE CAPLUS
L20 0 FILE BIOSIS
L21 0 FILE MEDLINE
L22 0 FILE EMBASE

```
L23             0 FILE USPATFULL

TOTAL FOR ALL FILES
L24             0 L6 AND CD8

=> 16 and multimer
L25             0 FILE CAPLUS
L26             0 FILE BIOSIS
L27             0 FILE MEDLINE
L28             0 FILE EMBASE
L29             0 FILE USPATFULL

TOTAL FOR ALL FILES
L30             0 L6 AND MULTIMER

=> l12 and CD8
L31             0 FILE CAPLUS
L32             0 FILE BIOSIS
L33             0 FILE MEDLINE
L34             0 FILE EMBASE
L35             0 FILE USPATFULL

TOTAL FOR ALL FILES
L36             0 L12 AND CD8

=> l12 and multimer
L37             0 FILE CAPLUS
L38             0 FILE BIOSIS
L39             0 FILE MEDLINE
L40             0 FILE EMBASE
L41             0 FILE USPATFULL

TOTAL FOR ALL FILES
L42             0 L12 AND MULTIMER

=>
<------User Break------>

=> file .jacob
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                14.40      14.61

FILE 'CAPLUS' ENTERED AT 13:44:16 ON 22 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:44:16 ON 22 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 13:44:16 ON 22 JUL 2003

FILE 'EMBASE' ENTERED AT 13:44:16 ON 22 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'USPATFULL' ENTERED AT 13:44:16 ON 22 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> lang f/au
L43           273 FILE CAPLUS
L44           678 FILE BIOSIS
L45           552 FILE MEDLINE
L46           572 FILE EMBASE
```

```
L47           0 FILE USPATFULL

TOTAL FOR ALL FILES
L48        2075 LANG F/AU

=> bonneville m/au
L49          20 FILE CAPLUS
L50          73 FILE BIOSIS
L51         130 FILE MEDLINE
L52         132 FILE EMBASE
L53           0 FILE USPATFULL

TOTAL FOR ALL FILES
L54         355 BONNEVILLE M/AU

=> l48 and l54
L55           1 FILE CAPLUS
L56           1 FILE BIOSIS
L57           5 FILE MEDLINE
L58           6 FILE EMBASE
L59           0 FILE USPATFULL

TOTAL FOR ALL FILES
L60          13 L48 AND L54

=> dup rem
ENTER L# LIST OR (END):l60
PROCESSING COMPLETED FOR L60
L61           7 DUP REM L60 (6 DUPLICATES REMOVED)

=> d l61 ibib abs total

L61  ANSWER 1 OF 7  EMBASE  COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER:   2002027403  EMBASE
TITLE:              CD8: From coreceptor to comodulator.
AUTHOR:             Bonneville M.; Lang F.
CORPORATE SOURCE:   M. Bonneville, INSERM U463, Institut de Biologie, Nantes,
                    France. bonnevil@nantes.inserm.fr
SOURCE:             Nature Immunology, (2002) 3/1 (12-14).
                    Refs: 11
                    ISSN: 1529-2908  CODEN: NIAMCZ
COUNTRY:            United States
DOCUMENT TYPE:      Journal; Article
FILE SEGMENT:       026     Immunology, Serology and Transplantation
                    029     Clinical Biochemistry
LANGUAGE:           English

L61  ANSWER 2 OF 7     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:   2001227369     MEDLINE
DOCUMENT NUMBER:    21135479   PubMed ID: 11241274
TITLE:              Frequent recognition of BCRF1, a late lytic cycle protein
                    of Epstein-Barr virus, in the HLA-B*2705 context: evidence
                    for a TAP-independent processing.
AUTHOR:             Saulquin X; Bodinier M; Peyrat M A; Hislop A; Scotet E;
                    Lang F; Bonneville M; Houssaint E
CORPORATE SOURCE:   INSERM U463, Institut de Biologie, Nantes, France.
SOURCE:             EUROPEAN JOURNAL OF IMMUNOLOGY, (2001 Mar) 31 (3) 708-15.
                    Journal code: 1273201. ISSN: 0014-2980.
PUB. COUNTRY:       Germany: Germany, Federal Republic of
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        200104
ENTRY DATE:         Entered STN: 20010502
```

Last Updated on STN: 20010502
Entered Medline: 20010426

AB Using a transient COS transfection assay, allowing a rapid estimation of the dominant CD8(+) T cell responses against a large number of HLA/viral protein combinations within polyclonal cell lines, we searched for HLA-B*2705-restricted CD8 T cell responses to Epstein-Barr virus (EBV) within T cell samples enriched for EBV-reactive cells. Among the 18 EBV proteins tested, only 2, the latent protein EBNA3A and the late lytic protein BCRF1 (viral IL-10), appeared dominant in the B27 context, as they triggered significant TNF and cytolytic responses in some donors. We provide evidence that the B27/BCRF1 epitope (RRLVVTLQC) is located in the signal sequence and that it can be presented in a TAP-independent manner. Using B27/BCRF1 monomeric complexes coated on immunomagnetic beads, we sorted out BCRF1-specific CD8 T cells from 8 of 15 HLA-B27(+) donors. This is, to our knowledge, the first demonstration of a recognition of BCRF1, suggesting that some immune control against EBV exists even during the late stage of the lytic cycle. This result also strengthens the unusual ability of HLA-B*2705 to present peptide in a TAP-independent manner.

L61 ANSWER 3 OF 7 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2001036060 EMBASE
TITLE: Efficient detection and immunomagnetic sorting of specific T cells using MHC class I/peptide multimers with reduced CD8 binding. (Nature medicine) 2001, 7: (1) 65.
AUTHOR: Bodinier M.; Peyrat M.-A.; Tournay C.; Davodeau F.; Romagne F.; **Bonneville M.**; **Lang F.**
SOURCE: Nature Medicine, (2001) 7/1 (129).
ISSN: 1078-8956 CODEN: NAMEFT
COUNTRY: United States
DOCUMENT TYPE: Journal; Errata
FILE SEGMENT: 026 Immunology, Serology and Transplantation
LANGUAGE: English

L61 ANSWER 4 OF 7 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2000296869 MEDLINE
DOCUMENT NUMBER: 20296869 PubMed ID: 10835691
TITLE: Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding.
COMMENT: Erratum in: Nat Med 2001 Jan;7(1):129
AUTHOR: Bodinier M; Peyrat M A; Tournay C; Davodeau F; Romagne F; **Bonneville M**; **Lang F**
CORPORATE SOURCE: INSERM U463, 9 quai Moncousu, Nantes, France.
SOURCE: NATURE MEDICINE, (2000 Jun) 6 (6) 707-10.
Journal code: 9502015. ISSN: 1078-8956.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200007
ENTRY DATE: Entered STN: 20000810
Last Updated on STN: 20010702
Entered Medline: 20000724

L61 ANSWER 5 OF 7 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 1999282915 MEDLINE
DOCUMENT NUMBER: 99282915 PubMed ID: 10352247
TITLE: Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities.
AUTHOR: Couedel C; Bodinier M; Peyrat M A; **Bonneville M**; Davodeau F; **Lang F**

CORPORATE SOURCE: Institut National de la Sante et de la Recherche Medicale, U463, Institute of Biology, Department of Pharmacology, College of Pharmacy, Nantes, France.
SOURCE: JOURNAL OF IMMUNOLOGY, (1999 Jun 1) 162 (11) 6351-8. Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199906
ENTRY DATE: Entered STN: 19990628
Last Updated on STN: 19990628
Entered Medline: 19990616

AB Recent studies have suggested that the diversity of TCR repertoire after primary immunization is conserved in memory T cells and that a progressive narrowing of this repertoire may take place during recall infections. It now remains to be investigated which parameters determine the repertoire of the memory response and possibly restrict its diversity after subsequent antigenic challenges. To address this question, we took advantage of a panel of CD8+ T cell clones from the joint of a rheumatoid arthritis patient and selected for their reactivity against a single MHC/peptide complex. Characterization of both TCR chains documented a great diversity among those clones and the persistence of clonotypes over a 2-yr period. Strikingly, despite the observed repertoire heterogeneity, all clones displayed a narrow range of MHC/peptide density requirements in cytotoxicity assays (ED50 between 9 and 36 nM). TCR affinities were then indirectly estimated by blocking CD8 interaction with an anti-CD8 mAb. We found a wide range of TCR affinities among the different clonotypes that segregated with Vbeta usage. We thus propose that during an in vivo chronic response, a narrow range of avidity of the TCR-CD8 complex conditions long-term clonotype persistence, and that the level of CD8 contribution is adjusted to keep clonotypes with variable TCR affinities within this avidity window.

L61 ANSWER 6 OF 7 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 95270993 MEDLINE
DOCUMENT NUMBER: 95270993 PubMed ID: 7751641
TITLE: Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands.
AUTHOR: **Lang F**; Peyrat M A; Constant P; Davodeau F; David-Ameline J; Poquet Y; Vie H; Fournie J J; **Bonneville M**
CORPORATE SOURCE: INSERM U211, Institute of Biology, Nantes, France.
SOURCE: JOURNAL OF IMMUNOLOGY, (1995 Jun 1) 154 (11) 5986-94. Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199506
ENTRY DATE: Entered STN: 19950629
Last Updated on STN: 19950629
Entered Medline: 19950622

AB Human V gamma 9V delta 2 T cells were shown recently to respond to nonpeptidic phosphorylated molecules of mycobacterial origin (previously referred to as TUBag). To investigate the early events of V gamma 9V delta 2 T cell activation, we have analyzed induction of cytotoxicity and TNF production of T cell clones by these molecules. We showed that within minutes after exposure, TUBag induced cytotoxicity of V gamma 9V delta 2 CTL (but not of CTL expressing other TCR V gamma/V delta or V alpha/V beta regions) against a broad set of target cells, including effector cells themselves. Induction of V gamma 9V delta 2 cytotoxicity by TUBag was blocked by anti-TCR mAbs and was abrogated after dephosphorylation of

TUBag. Similarly, TUBag, but not dephosphorylated TUBag, induced massive TNF production by V gamma 9V delta 2 T cell clones only, which already was significant 20 min after exposure. Of note, only basal amounts of TNF were produced when cells were maintained in suspension in the presence of TUBag, indicating that efficient activation of TNF production induced by these compounds required a cell-to-cell contact. Finally, preincubation experiments allowed us to demonstrate that activation of V gamma 9V delta 2 T cells was strictly dependent on the presence of TUBag because preincubation of the targets with TUBag followed by a single wash abrogated the activation. Taken together, these results strongly suggest that activation of V gamma 9V delta 2 cells by TUBag occurs after binding of these compounds to (a) yet unidentified, highly conserved, and broadly distributed molecule(s). The results also suggest either that TUBag induces a very rapid and transient expression of a V gamma 9V delta 2 TCR ligand or, more likely, that TUBag is a low affinity component of a complex recognized by the V gamma 9V delta 2 TCR.

L61 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 1985:534700 CAPLUS
DOCUMENT NUMBER: 103:134700
TITLE: Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice
AUTHOR(S): Sestier, C.; Odent-Pogu, S.; **Bonneville, M.**; Maurel, C.; **Lang, F.**; Sai, P.
CORPORATE SOURCE: Physiol. Pharmacol. Dep., Vet. Sch., Nantes, 44026, Fr.
SOURCE: Immunology Letters (1985), 10(1), 57-60
CODEN: IMLED6; ISSN: 0165-2478
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study concerns the effect of a 12-day cyclosporin A (CsA) [59865-13-3] treatment (50 mg/kg/day) on autoimmune diabetes induced by 5 low doses (40 mg per kg/day) of streptozotocin (SZ). The SZ-treatment period was initiated 4 days after initial administration of CsA. In young (45-day) CD-1 male mice, CsA enhanced hyperglycemia, hypoinsulinemia, and .beta.-cell destruction following multiple low-dosage SZ treatment. Moreover, CsA did not prevent development of insulinitis induced concomitantly by SZ. Similarly, CsA enhanced the toxic diabetes produced by a single high dose (160 mg/kg) of SZ. Furthermore, in the absence of SZ, CsA alone induced glucose intolerance, assocd. with .beta.-cell degranulation and high pancreatic CsA content. The enhancement of SZ-induced diabetes by CsA may thus be due to toxicity of the immunosuppressive agent for pancreatic .beta.-cells. This side effect is noteworthy because CsA is currently being used in the therapy of human insulin-dependent diabetes.

```
   research.  Use for software development or design or implementation
   of commercial gateways or other similar uses is prohibited and may
   result in loss of user privileges and other penalties.

   * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:59:24 ON 22 JUL 2003

=> file .jacob
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:59:33 ON 22 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:59:33 ON 22 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 15:59:33 ON 22 JUL 2003

FILE 'EMBASE' ENTERED AT 15:59:33 ON 22 JUL 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:59:33 ON 22 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> MHC(10A)CD8
L1          1698 FILE CAPLUS
L2          1577 FILE BIOSIS
L3          1552 FILE MEDLINE
L4          1678 FILE EMBASE
L5          1010 FILE USPATFULL

TOTAL FOR ALL FILES
L6          7515 MHC(10A) CD8

=> l6 same binding
MISSING OPERATOR L6 SAME
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> l6(P)binding(P)(reduce or diminish or suppress)
L7             5 FILE CAPLUS
L8             5 FILE BIOSIS
L9             6 FILE MEDLINE
L10            6 FILE EMBASE
L11            5 FILE USPATFULL

TOTAL FOR ALL FILES
L12           27 L6(P) BINDING(P)(REDUCE OR DIMINISH OR SUPPRESS)

=> dup rem
ENTER L# LIST OR (END):l12
PROCESSING COMPLETED FOR L12
L13            13 DUP REM L12 (14 DUPLICATES REMOVED)

=> l13(P)alter(3A)amino
L14            5 S L13
L15            0 FILE CAPLUS
L16            3 S L13
L17            0 FILE BIOSIS
```

```
L18             0 S L13
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L18(P)ALTER'
L19             0 FILE MEDLINE
L20             0 S L13
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L20(P)ALTER'
L21             0 FILE EMBASE
L22             5 S L13
L23             3 FILE USPATFULL

TOTAL FOR ALL FILES
L24             3 L13(P) ALTER(3A) AMINO

=> d l24 ibib abs total

L24  ANSWER 1 OF 3  USPATFULL on STN
ACCESSION NUMBER:         2003:106233  USPATFULL
TITLE:                    Compositions and methods for the therapy and diagnosis
                          of pancreatic cancer
INVENTOR(S):              Benson, Darin R., Seattle, WA, UNITED STATES
                          Kalos, Michael D., Seattle, WA, UNITED STATES
                          Lodes, Michael J., Seattle, WA, UNITED STATES
                          Persing, David H., Redmond, WA, UNITED STATES
                          Hepler, William T., Seattle, WA, UNITED STATES
                          Jiang, Yuqiu, Kent, WA, UNITED STATES
PATENT ASSIGNEE(S):       Corixa Corporation, Seattle, WA, UNITED STATES, 98104
                          (U.S. corporation)

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2003073144      A1   20030417
APPLICATION INFO.:        US 2002-60036      A1   20020130  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2001-333626P    20011127 (60)
                          US 2001-305484P    20010712 (60)
                          US 2001-265305P    20010130 (60)
                          US 2001-267568P    20010209 (60)
                          US 2001-313999P    20010820 (60)
                          US 2001-291631P    20010516 (60)
                          US 2001-287112P    20010428 (60)
                          US 2001-278651P    20010321 (60)
                          US 2001-265682P    20010131 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                          AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:         17
EXEMPLARY CLAIM:          1
LINE COUNT:               14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Compositions and methods for the therapy and diagnosis of cancer,
        particularly pancreatic cancer, are disclosed. Illustrative compositions
        comprise one or more pancreatic tumor polypeptides, immunogenic portions
        thereof, polynucleotides that encode such polypeptides, antigen
        presenting cell that expresses such polypeptides, and T cells that are
        specific for cells expressing such polypeptides. The disclosed
        compositions are useful, for example, in the diagnosis, prevention
        and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

L24 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of colon cancer

INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150922	A1	20021017
APPLICATION INFO.:	US 2001-998598	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer

INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1
LINE COUNT: 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.